Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Felipe SamaniegoThe University of Texas MD Anderson Cancer Center, Houston, TexasCorrespondence[email protected]

Peter McLaughlinThe University of Texas MD Anderson Cancer Center, Houston, Texas

Sattva S. NeelapuThe University of Texas MD Anderson Cancer Center, Houston, Texas

Lei FengThe University of Texas MD Anderson Cancer Center, Houston, Texas

Michelle FanaleThe University of Texas MD Anderson Cancer Center, Houston, Texas

Loretta NastoupilThe University of Texas MD Anderson Cancer Center, Houston, Texas

Maria Alma RodriguezThe University of Texas MD Anderson Cancer Center, Houston, Texas

Barbara ProThe University of Texas MD Anderson Cancer Center, Houston, Texas

Erin TaylorThe University of Texas MD Anderson Cancer Center, Houston, Texas

Fredrick B. HagemeisterThe University of Texas MD Anderson Cancer Center, Houston, Texas

Nathan FowlerThe University of Texas MD Anderson Cancer Center, Houston, Texas

Your download is now in progress and you may close this window